Coherus Oncology, Inc.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Shri ThanedarHouse · D · MI |
CHRSCoherus Oncology, Inc. · Stock |
Sale $15,001 - $50,000 |
Feb 9, 2023 | Jan 23, 2023 | Filing ↗ |
Whale Activity
- Increased40
- New16
- Held30
- Decreased46
- Closed28
- No prior filing3
| Filer | Shares | Value | Change |
|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 13.1M | $15.8M | held |
| BlackRock, Inc. | 11.7M | $14.2M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.6M | $6.8M | decreased |
| Samsara BioCapital, LLC | 3.4M | $4.1M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 3.1M | $3.8M | decreased |
| Kohlberg Kravis Roberts & Co. L.P. | 3.0M | $3.6M | held |
| STATE STREET CORP | 2.4M | $2.9M | increased |
| CM Management, LLC | 2.1M | $2.5M | held |
| GOLDMAN SACHS GROUP INC | 2.0M | $2.4M | increased |
| C WorldWide Group Holding A/S | 1.9M | $2.3M | held |
| ADAR1 Capital Management, LLC | 1.9M | $2.3M | increased |
| Hudson Bay Capital Management LP | 1.7M | $2.1M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Satvat Ali J.Director | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Karachun Rita ADirector | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Newcomer Lee NisleyDirector | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Ryan Michael LeeDirector | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| O'Donnell-Tormey JillDirector | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Wahlstrom MatsDirector | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Newton Charles W.Director | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Lanfear Dennis MPresident & CEO · Director | Grant / award | +375.0K | $0.00 | $0 | Jan 23, 2026 | Form 4 ↗ |
| McMichael Bryan JChief Financial Officer | Grant / award | +112.5K | $0.00 | $0 | Jan 22, 2026 | Form 4 ↗ |
| McMichael Bryan JChief Financial Officer | Tax withholding | −1,715 | $1.55 | $3K | Jan 20, 2026 | Form 4 ↗ |
| Lanfear Dennis MPresident & CEO · Director | Tax withholding | −11.8K | $1.55 | $18K | Jan 20, 2026 | Form 4 ↗ |
| Wahlstrom MatsDirector | Sale | −100.0K | $0.74 | $74K | May 23, 2025 | Form 4 ↗ |
| McMichael Bryan JChief Financial Officer | Tax withholding | −1,711 | $1.39 | $2K | Jan 20, 2025 | Form 4 ↗ |
| Reider PaulChief Commercial Officer | Tax withholding | −4,858 | $1.39 | $7K | Jan 20, 2025 | Form 4 ↗ |
| Lanfear Dennis MPresident & CEO · Director | Tax withholding | −11.8K | $1.39 | $16K | Jan 20, 2025 | Form 4 ↗ |
| McMichael Bryan JChief Financial Officer | Tax withholding | −1,711 | $1.57 | $3K | Jan 7, 2025 | Form 4 ↗ |
| Lanfear Dennis MPresident & CEO · Director | Tax withholding | −11.8K | $1.66 | $20K | Jan 4, 2025 | Form 4 ↗ |
| Reider PaulChief Commercial Officer | Tax withholding | −2,277 | $1.66 | $4K | Jan 4, 2025 | Form 4 ↗ |
| Reider PaulChief Commercial Officer | Tax withholding | −2,073 | $1.61 | $3K | Dec 13, 2024 | Form 4 ↗ |
| Wahlstrom MatsDirector | Gift | +100.0K | $0.00 | $0 | Feb 9, 2024 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.0M | $5.5M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.2M | $4.5M | 0.01% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $2.6M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.4M | $2.0M | 0.01% | Jul 31, 2026 |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 900.0K | $1.3M | 0.17% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund BlackRock Funds | 927.8K | $1.3M | 0.02% | Aug 31, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 741.5K | $1.0M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 763.0K | $1.0M | 0.00% | Aug 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 747.1K | $1.0M | 0.01% | Aug 31, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 702.7K | $949K | 0.00% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list CHRS's shares (CUSIP 19249H103), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Corporate Lobbying
No lobbying filings found naming Coherus Oncology, Inc. as the client.
Government Contracts
No federal contract awards found for Coherus Oncology, Inc..
U.S. Patents
No USPTO patent applications found for Coherus Oncology, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$181.1M | -$199.7M | -$203.2M | -$256.9M | -$263.9M |
| Net income | $168.0M | $28.5M | -$237.9M | -$291.8M | -$287.1M |
| Diluted EPS | $1.43 | $0.25 | -$2.53 | -$3.76 | -$3.81 |
| Operating cash flow | -$138.5M | -$20.4M | -$174.9M | -$241.1M | -$37.4M |
| Cash and equivalents | $88.9M | $126.0M | $102.9M | $63.5M | $417.2M |
| Total assets | $258.3M | $448.5M | $629.6M | $480.8M | $679.3M |
| Total liabilities | $197.3M | $580.5M | $823.0M | $618.3M | $581.6M |
| Shareholders' equity | $61.0M | -$132.0M | -$193.4M | -$137.4M | $97.7M |
As Coherus Oncology, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 9, 2026 ↗
Stock Splits
No stock splits in CHRS's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsOct 29, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsAug 28, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsAug 17, 2026
EDGAR ↗ - 8-K · Items 1.01, 1.02, 2.03, 9.01Material agreement · Termination of agreement · Direct financial obligationAug 17, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
EDGAR ↗ - 8-K · Items 4.01, 9.01Change in auditorJun 15, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
EDGAR ↗

